PLoS ONE (Jan 2013)

Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.

  • Jonathan Plumb,
  • Laura Robinson,
  • Simon Lea,
  • Antonia Banyard,
  • John Blaikley,
  • David Ray,
  • Andrea Bizzi,
  • Giorgina Volpi,
  • Fabrizio Facchinetti,
  • Dave Singh

DOI
https://doi.org/10.1371/journal.pone.0064257
Journal volume & issue
Vol. 8, no. 5
p. e64257

Abstract

Read online

Previous studies of glucocorticoid receptor (GR) function in COPD lung macrophages have used dexamethasone to evaluate inhibition of cytokine production. We have now used the clinically relevant corticosteroid beclomethasone-17-monopropionate (17-BMP) to assess GR function in COPD lung macrophages, and investigated the transactivation of glucocorticoid sensitive genes and GR phosphorylation in addition to cytokine production. Lung macrophages were purified from surgically acquired lung tissue, from patients with COPD, smokers, and non-smokers. The transactivation of glucocorticoid sensitive genes (FKBP51 and GILZ) by 17-BMP were analysed by polymerase chain reaction. 17-BMP suppression of LPS-induced TNFα, IL-6 and CXCL8 was measured by ELISA and GR phosphorylation was measured by immunohistochemistry and Western blot. 17-BMP reduced cytokine release in a concentration dependent manner, with >70% inhibition of all cytokines, and no difference between COPD patients and controls. Similarly, the transactivation of FKBP51 and GILZ, and GR phosphorylation was similar between COPD patients and controls. In this context, GR function in COPD lung macrophages is unaltered. 17-BMP effectively suppresses cytokine production in COPD lung macrophages.